Anna Pesci

Dr. Anna Pesci

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2012 in BMC Cancer
Verified
Journal Article
Open access
PDF file
ATAnna Torres
Anna Torres
KTKamil Torres
Kamil Torres
APAnna Pesci
Anna Pesci
MCMarcello Ceccaroni
Marcello Ceccaroni
TPTomasz Paszkowski
Tomasz Paszkowski
RMRyszard Maciejewski
Ryszard Maciejewski
Alterations of mTOR gene expression have been implicated in the pathogenesis of endometrioid endometrial cancer however only few studies explored the cause of increased mTOR activation in this malignancy. miRNAs are small, noncoding RNAs, which were proven to regulated gene expression at the posttranscriptional level. The study aimed to explore deregulation of miRNAs targeting mTOR kinase (miR-99a, miR-100 and miR-199b) as a possible cause of its altered expression in EEC tissues. In addition expression of the three miRNAs was investigated in plasma of EEC patients and was assessed in terms of diagnostic and prognostic utility.

31 August 2022 in International Journal of Gynecological Pathology
Verified
Journal Article
Open access
SSSimona Stolnicu
Simona Stolnicu
LHLynn Hoang
Lynn Hoang
QZQin M.A. Zhou
Qin M.A. Zhou
AIAlexia Iasonos
Alexia Iasonos
CTCristina Terinte
Cristina Terinte
JHJoshua Honeyman
Joshua Honeyman
Although both the 2014 and 2020 World Health Organization (WHO) criteria require unequivocal glandular and squamous differentiation for a diagnosis of cervical adenosquamous carcinoma (ASC), in practice, ASC diagnoses are often made in tumors that lack unequivocal squamous and/or glandular differentiation. Considering the ambiguous etiologic, morphologic, and clinical features and outcomes associated with ASCs, we sought to redefine these tumors. We reviewed slides from 59 initially diagnosed ASCs (including glassy cell carcinoma and related lesions) to confirm an ASC diagnosis only in the presence of unequivocal malignant glandular and squamous differentiation. Select cases underwent immunohistochemical profiling as well as human papillomavirus (HPV) testing by in situ hybridization. Of the 59 cases originally classified as ASCs, 34 retained their ASC diagnosis, 9 were reclassified as pure invasive stratified mucin-producing carcinomas, 10 as invasive stratified mucin-producing carcinomas with other components (such as HPV-associated mucinous, usual-type, or ASCs), and 4 as HPV-associated usual or mucinous adenocarcinomas with benign-appearing squamous metaplasia. Two glassy adenocarcinomas were reclassified as poorly differentiated HPV-associated carcinomas based on morphology and immunophenotype. There were no significant immunophenotypic differences between ASCs and pure invasive stratified mucin-producing carcinomas with regard to HPV and other markers including p16 expression. Although limited by a small sample size, survival outcomes seemed to be similar between all groups. ASCs should be diagnosed only in the presence of unequivocal malignant glandular and squamous differentiation. The 2 putative glassy cell carcinomas studied did not meet our criteria for ASC and categorizing them as such should be reconsidered.

1 March 2012 in Human Pathology
Verified
Journal Article
Closed access
APAnna Pesci
Anna Pesci
PCPaola Castelli
Paola Castelli
EFEnrico Facci
Enrico Facci
LRLuigi Romano
Luigi Romano
GZGiuseppe Zamboni
Giuseppe Zamboni

1 January 2018 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
SUStefano Uccella
Stefano Uccella
FFFrancesca Falcone
Francesca Falcone
SGStefano Greggi
Stefano Greggi
Francesco FanfaniFrancesco Fanfani
Francesco Fanfani
Pierandrea De IacoPierandrea De Iaco
Pierandrea De Iaco
FGFabio Ghezzi
Fabio Ghezzi
Uccella S, et al. J Gynecol Oncol. 2017 Dec;29:e100. https://doi.org/10.3802/jgo.2018.29.e100

7 March 2024 in Cancers
Verified
Journal Article
Open access
PDF file
APAndrea Puppo
Andrea Puppo
GOGiulio Fraternali Orcioni
Giulio Fraternali Orcioni
VCVALENTINO CLIGNON
VALENTINO CLIGNON
Yuri MusizzanoYuri Musizzano
Yuri Musizzano
CZCarla Angela Zavattero
Carla Angela Zavattero
Giuseppe MigliarettiGiuseppe Migliaretti
Giuseppe Migliaretti
No prospective study has validated molecular classification to guide adjuvant treatment in endometrial cancer (EC), and not even retrospective data are present for patients with morphological low-risk EC. We conducted a retrospective, multicenter, observational study including 370 patients with low-risk endometrioid EC to evaluate the incidence and prognostic role of p53 abnormal expression (p53abn) in this specific subgroup. Among 370 patients, 18 had abnormal expressions of p53 (4.9%). In 13 out of 370 patients (3.6%), recurrences were observed and two were p53abn. When adjusting for median follow-up time, the odds ratio (OR) for recurrence among those with p53abn versus p53 wild type (p53wt) was 5.23—CI 95% 0.98–27.95, p = 0.053. The most common site of recurrence was the vaginal cuff (46.2%). One recurrence occurred within the first year of follow-up, and the patient exhibited p53abn. Both 1-year and 2-year DFS rates were 94.4% and 100% in the p53abn and p53wt groups, respectively. One patient died from the disease and comprised p53wt. No difference in OS was registered between the two groups; the median OS was 21.9 months (16.4–30.1). Larger multicenter studies are needed to tailor the treatment of low-risk EC patients with p53abn. Performing molecular classification on all EC patients might be cost-effective, and despite the limits of our relatively small sample, p53abn patients seem to be at greater risk of recurrence, especially locally and after two years since diagnosis.

30 June 2011 in Surgical Pathology Clinics
Verified
Journal Article
Closed access
LBLaura Bortesi
Laura Bortesi
APAnna Pesci
Anna Pesci
GBGiuseppe Bogina
Giuseppe Bogina
PCPaola Castelli
Paola Castelli
GZGiuseppe Zamboni
Giuseppe Zamboni